Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone

100 Randomized Patients; Inspire’s CEO Tim Herbert appointed Chairman of the Board

MINNEAPOLIS, August 11, 2021 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that 100 patients have been randomized in the FDA pivotal AIRFLOW-3 Clinical Trial.  This COPD trial is evaluating the safety and effectiveness of the Nuvaira Lung Denervation System to reduce the risk of COPD exacerbations in patients on optimal medical care.

Nuvaira also announces that Tim Herbert, President & CEO of Minneapolis-based Inspire Medical Systems has been appointed Chairman of the Board of Directors.

“Despite the healthcare system challenges of the COVID pandemic, treatment of COPD exacerbations remains a critical unmet need” said Dennis Wahr, M.D., CEO of Nuvaira Inc.  “We applaud our trial investigators for their unwavering support of the AIRFLOW-3 trial and their commitment to enrollment.”  Over 250 patients have been randomized or treated with TLD in Nuvaira clinical trials, including over 50 patients in the United States.

Prof. Pallav Shah (Royal Brompton Hospital, London) randomized the 100th patient in the AIRFLOW-3 trial on August 11.  “We are thrilled to be part of AIRFLOW-3, and to build on the knowledge and experience with the therapy which has the potential to alter the clinical trajectory for COPD patients with persistent exacerbations.” Prof. Shah said.  “We are proud to help Nuvaira and our colleagues celebrate this milestone and look forward to offering TLD as a therapeutic option for many of our COPD patients who struggle to maintain clinical stability on routine pharmacotherapy.”  Professor Shah and his team have randomized or treated over 40 patients in TLD clinical trials, and currently are ranked #1 globally across AIRFLOW-3 trial centers.

The Nuvaira Lung Denervation System is a novel bronchoscopic procedure that disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity, which addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma. Nuvaira’s proprietary technology has demonstrated a positive safety profile and feasibility in three peer-reviewed published clinical studies in COPD patients.  A growing body of literature supports the therapeutic potential of Targeted Lung Denervation (TLD) to meet a significant unmet medical need in patients at risk of COPD exacerbations, also called “lung attacks”, which represent the major driver of healthcare cost and poor clinical prognosis.

About Nuvaira

Nuvaira is a privately held company headquartered in Minneapolis, MN. The company’s proprietary Nuvaira Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD).  The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA, and is CE Mark approved. Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.

Please visit our website and publication bibliographies at www.Nuvaira.com.

# # #

Media Inquiries:

Amy Wolter

+1 (763) 450-5676

info@nuvaira.com

Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation

AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group.

MINNEAPOLISNov. 23, 2020 /PRNewswire/ — Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded trial (AIRFLOW-2) that confirms long-term safety and durable effect of Targeted Lung Denervation (TLD) therapy in COPD patients.

TLD, a novel bronchoscopic procedure that disrupts pulmonary nerve input to the lung, has been developed to reduce the clinical consequences of neural hyperactivity, including airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma. Nuvaira’s proprietary TLD technology has demonstrated safety and feasibility in three completed clinical studies, and physician and patient interest in the therapy has enabled continued enrollment in Nuvaira’s FDA pivotal trial (AIRFLOW-3).

AIRFLOW-2 was a double-blinded, sham controlled, multicenter randomized clinical trial (RCT) to assess respiratory adverse events in 82 moderate-to-severe COPD patients with high symptom burden despite optimal drug therapy.  COPD exacerbations represent the highest proportion of COPD costs to the healthcare system and are associated with decreased lung function and poor quality of life.  Valipour and colleagues (Int J COPD 2020:15 2807-2816) confirmed that the risk of severe COPD exacerbation requiring hospitalization was significantly lower in the TLD treatment group compared to the control group through two years of follow-up (p=0.04).  Lung function and Quality of Life measures showed clinical stability in TLD-treated patients over two years of follow-up.

Five peer reviewed publications contribute to the growing body of evidence supporting the therapeutic potential of Targeted Lung Denervation to meet a significant unmet medical need in patients at risk of COPD exacerbation.

About Nuvaira
Nuvaira‘s proprietary Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD).  The Nuvaira® Lung Denervation System is CE Mark approved.  The Nuvaira® Lung Denervation System is under clinical investigation and is not commercially available in the USA. Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.
Please visit our clinical trial website www.airflowtrial.com and publication bibliographies at www.Nuvaira.com.

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors

MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA). This program creates an expedited pathway for prioritized FDA review of devices that have potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Nuvaira’s lung denervation system is designed to reduce the risk of moderate-to-severe COPD exacerbations in patients on optimal medical care. In March, FDA’s review of safety data on the first 50 patients enrolled in Nuvaira’s AIRFLOW-3 pivotal trial resulted in full IDE approval for completion of the 400-patient study, and in April, the Centers for Medicare & Medicaid Services (CMS) approved the AIRFLOW-3 trial for the purposes of Medicare coverage (42 CFR 405 Subpart B). These decisions are expected to support rapid FDA approval and positive reimbursement access in the U.S. market.

Nuvaira also announces appointment of Tim Herbert, President & CEO of Minneapolis-based Inspire Medical Systems to its Board of Directors.   Tim has led Inspire through FDA approval of the first interventional device for treatment of obstructive sleep apnea (OSA) in 2010, followed by a string of positive reimbursement coverage decisions in the U.S. and the company’s successful IPO in 2018. In addition, Nuvaira has added medtech veteran Karen Peterson as VP Clinical, Regulatory & Quality to its executive team.  Karen’s 30-year track record includes successful execution of multiple IDE clinical trials and PMA approvals. She joins Nuvaira from Stryker ENT (formerly Entellus Medical Inc.).

“Despite the challenges of the COVID pandemic, we are thrilled about these additions to our leadership team and the positive announcements from FDA and CMS.” said Dennis Wahr, M.D., CEO of Nuvaira Inc. “We support our global pulmonary thought-leaders who are working hard to ensure patient access to routine care and to important clinical trials like AIRFLOW-3, while simultaneously adapting to the new reality of COVID-19”.

The Nuvaira Lung Denervation System is a novel bronchoscopic procedure that disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity, which addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma. Nuvaira’s proprietary technology has demonstrated safety and feasibility in three peer-reviewed published clinical studies in COPD patients. A growing body of literature supports the therapeutic potential of Targeted Lung Denervation (TLD) to meet a significant unmet medical need in patients at risk of COPD exacerbations, also called “lung attacks”, which represent the major driver of healthcare cost and poor clinical prognosis.

About Nuvaira

Nuvaira is a privately held company headquartered in Minneapolis, MN. The company’s proprietary Nuvaira Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD). The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA, and is CE Mark approved. Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.

Please visit our website and publication bibliographies at www.Nuvaira.com.

# # #

Media Inquiries:

Amy Wolter

+1 (763) 450-5676

info@nuvaira.com

Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone

Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team

MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that Tom Griffin has joined Nuvaira as Chief Financial Officer.

Tom Griffin has a 30-year track record of strong leadership guiding high-growth companies through investment financing, rapid commercialization growth and initial public offering stages.  Tom was most recently Chief Financial Officer of Avedro, Inc. (NASDAQ: AVDR) a leading hybrid ophthalmic pharmaceutical and medical technology company. Avedro completed its initial public offering in February 2019 and was acquired by Glaukos Corporation (NYSE: GKOS) in November 2019.  Prior to joining Avedro, Tom served as the Chief Financial Officer of Entellus Medical, Inc., (NASDAQ: ENTL) from 2007 to May 2016, guiding the company through its initial public offering in 2015.  Entellus was acquired by Stryker Corporation in February 2018.

“We are thrilled that Tom has joined our team,” said Dennis Wahr, M.D., chief executive officer at Nuvaira. “His experience guiding start-up medical device companies through the critical clinical development phase with successful transition to commercial growth and public market offerings will be critical to Nuvaira’s continued progress and success.”

“Joining Nuvaira represents an extraordinary opportunity for me to be part of a dynamic and pioneering company that is deploying truly disruptive technologies that will benefit patients and provide value to physicians and the healthcare system,” said Mr. Griffin.  “The company has an exciting vision for development of its therapy and I am looking forward to working with the team to achieve Nuvaira’s strategic and financial growth objectives.”

The company’s dNerva® Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma in a procedure called Targeted Lung Denervation (TLD). Nuvaira’s proprietary technology has demonstrated safety and feasibility in three completed clinical studies: IPS-I/II, AIRFLOW-1, and most recently, the AIRFLOW-2 sham controlled randomized clinical trial (RCT), which was recently published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), a top-tier global medical journal.  Nuvaira’s pivotal AIRFLOW-3 trial is currently enrolling patients in the US, Canada and Europe, and has just reached the 50-patient enrollment milestone.  Nearly 200 patients have now been treated with targeted lung denervation in clinical trials since 2012.

About Nuvaira

Nuvaira is a privately held company headquartered in Minneapolis, Minn. The company has developed the dNerva® Lung Denervation System to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves with Targeted Lung Denervation (TLD). The dNerva® Lung Denervation system is CE Mark approved.  The dNerva® Lung Denervation system is under clinical investigation and is not commercially available in the USA . Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.   Please visit us at www.Nuvaira.com.

# # #

Media Inquiries:

Amy Wolter

+1 (763) 450-5676

info@nuvaira.com